Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the Cardiff experimental cancer medicine centre to establish the feasibility of combining the tyrosine kinase inhibitor, ponatinib with chemotherapy in patients with acute myeloid leukaemia with a flt3 mutation.

Next Previous
X
Search
Trial Profile

A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the Cardiff experimental cancer medicine centre to establish the feasibility of combining the tyrosine kinase inhibitor, ponatinib with chemotherapy in patients with acute myeloid leukaemia with a flt3 mutation.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms AML19 Pilot

    • Most Recent Events

    • 18 Jul 2015 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 21 Dec 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top